The goal of this white paper is to provide OHPs with updated, evidence-based FDI guidance and tools on the prevention and detection of HPV-associated OPSCC. It is intended to complement, not replace, existing clinical guidance. By recognizing OHPs as important partners in HPV prevention, policymakers, healthcare systems, and initiatives can help close the current gaps in prevention, public awareness and vaccine uptake to reduce the future burden of HPV-associated OPSCC.